Biotechnology
News Category
Lexaria Announces Reverse Stock Split to Regain Nasdaq Compliance
Lexaria Bioscience Corp. will effect a 1-for-15 reverse stock split on August 3, 2026, to increase its share price and meet Nasdaq's minimum bid price...
VolitionRx Highlights Growing Clinical Evidence Supporting Nu.Q NETs Test for Sepsis and NETosis-Related Diseases
VolitionRx announces that multiple peer-reviewed studies support its Nu.Q H3.1 test as a biomarker for sepsis, capable of distinguishing it from non-i...
Instinct Bio and INVITRX Partner to Bring GENREVER to U.S. and Boost Regenerative Medicine in Indonesia
Instinct Bio announced a strategic collaboration with INVITRX to manufacture and sell GENREVER cosmetic products in the U.S. and support regenerative ...
Renaissance BioScience Appoints Dr. James Tansey to Board of Directors
Renaissance BioScience Corp. appoints Dr. James Tansey, a seasoned entrepreneur and academic, to its board, bringing expertise in technology commercia...
BRAIN Biotech AG Names Dr. Sven K. Weber as New CEO, Succeeding Adriaan Moelker
Dr. Sven K. Weber will become CEO of BRAIN Biotech AG on October 1, 2026, bringing extensive experience in the industrial enzyme business from BASF, a...
VERAXA Biotech Expands Patent Portfolio to Protect Next-Generation Cancer Therapy Platforms
VERAXA Biotech has expanded its intellectual property portfolio with new patent filings covering its BiTAC-TCE and BiTAC-ADC platforms, strengthening ...
MindBio Therapeutics Delivers First Edge AI Kiosk Prototypes for Rapid Impairment Screening in Workplace Safety
MindBio Therapeutics has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, using voice analysis with over...
VERAXA Biotech Appoints Dr. Christoph Erkel as Chief Scientific Officer to Advance BiTAC(R) Cancer Therapy Platform
VERAXA Biotech strengthens its scientific leadership with Dr. Christoph Erkel as CSO, signaling progress for its BiTAC(R) platform and oncology pipeli...
VERAXA Biotech Expands Patent Portfolio to Strengthen Next-Generation Cancer Therapy Platforms
VERAXA Biotech AG announced the expansion of its intellectual property portfolio with new patent filings, bringing its total to over 50 granted patent...
Greenland Mines Secures Canadian Patent for Klotho Gene Therapy Technology, Advancing Neurological Treatments
Greenland Mines (GRML) obtained a Canadian patent for Klotho-based gene therapies targeting cognition and neurodegenerative diseases, expanding its IP...
Quantum BioPharma Outlines Lucid-MS Development and Commercial Growth Strategy
Quantum BioPharma's executive discusses the company's strategy for advancing Lucid-MS into Phase 2 trials and the commercial potential of unbuzzd, hig...
VERAXA Biotech Shareholders Overwhelmingly Approve Governance and Financing Measures
VERAXA Biotech shareholders approved corporate governance and financing measures with over 99.94% support, enabling greater flexibility for acquisitio...
Greenland Mines Secures Canadian Patent for Klotho Gene Therapy Targeting Neurodegenerative Diseases
Greenland Mines Ltd. announced a Canadian patent for its Klotho-based gene therapy technology, protecting intellectual property for treatments targeti...
NanoViricides Awaits Regulatory Decision on Ebola Trial for NV-387 Oral Gummies
NanoViricides is awaiting regulatory approval in the DRC to begin a Phase II trial of its NV-387 Oral Gummies for the Bundibugyo ebolavirus, which cur...
Lantern Pharma's LP-184 Cleared by EMA for Bladder Cancer Trial in Europe
Lantern Pharma received EMA clearance for an investigator-initiated Phase 1b/2 trial of LP-184 in advanced or metastatic bladder cancer, advancing its...
GeoVax Reports Second Quarter 2026 Financial Results and Advances GEO-MVA Toward Pivotal Study
GeoVax provides business update highlighting progress toward initiating a pivotal immunobridging study for its GEO-MVA vaccine under an expedited regu...
VERAXA Biotech Advances Bispecific ADC Program Under OmniAb Collaboration
VERAXA Biotech's bispecific ADC program VXA-222 hits a key milestone under its OmniAb collaboration, advancing to the next phase of development for pr...
Quantum BioPharma Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans
Quantum BioPharma's executive discusses the company's strategy for advancing Lucid-MS, a multiple sclerosis drug candidate, and its commercial product...
Onco-Innovations Advances Lead Oncology Candidate ONC010 Toward Clinical Studies
Onco-Innovations is progressing its lead PNKP inhibitor ONC010 by scaling up manufacturing and securing partnerships to support future clinical trials...
Tonix Pharmaceuticals Schedules Second-Quarter 2026 Results Call for Aug. 10
Tonix Pharmaceuticals will report its second-quarter 2026 financial results and operational highlights on August 10, 2026, providing investors with ke...
VERAXA Biotech and OmniAb Advance Bispecific ADC Program VXA-222 Following Key Milestone
VERAXA Biotech AG announced its bispecific ADC program VXA-222 has passed a key technical milestone under its OmniAb collaboration, moving the precisi...
Onco-Innovations Integrates PNKP Inhibition, Nanoparticle Delivery, and AI to Address Key Challenges in Cancer Drug Development
Onco-Innovations combines a novel DDR target, nanoparticle delivery, and causal AI to tackle drug resistance, trial design, and delivery challenges in...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Accelerate Cancer Therapy Development
VERAXA Biotech AG appoints Christoph Erkel, Ph.D., as Chief Scientific Officer to lead advancement of its proprietary BiTAC platform technologies for ...
VERAXA Biotech Receives Positive Regulatory Feedback from Germany for BiTAC®-TCE Program
VERAXA Biotech's receipt of Scientific Advice from Germany's Paul-Ehrlich-Institute supports the development strategy for its lead BiTAC®-TCE candidat...
Onco-Innovations Advances Precision Oncology with ONC010 as Biomarker-Driven Cancer Gains Momentum
Onco-Innovations Ltd. is advancing its lead nanoparticle-encapsulated PNKP inhibitor, ONC010, for biomarker-selected cancers, aligning with the indust...
Lantern Pharma Receives U.S. Patent Allowance for LP-184 Biomarker-Based Cancer Treatment Methods
Lantern Pharma announced a U.S. patent allowance for methods selecting patients for LP-184 based on a three-gene biomarker signature, enabling precisi...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Platform
VERAXA Biotech AG announced the appointment of Christoph Erkel as Chief Scientific Officer, leveraging his two decades of antibody therapeutics experi...
BioAdaptives Readies Manufacturing for Wellness Product Launch
BioAdaptives completes commercial manufacturing and supply chain setup to launch its MyndSystem and Xcellara wellness platforms, targeting cognitive a...
iOrganBio Appoints Lee L. Rubin, Ph.D. to Scientific Advisory Board to Advance Neurological Applications
iOrganBio has appointed Lee L. Rubin, Ph.D., a leading stem cell biologist and Harvard professor, to its Scientific Advisory Board, aiming to leverage...
Creative Biolabs Expands Microfluidics Solutions to Accelerate High-Throughput Antibody Discovery
Creative Biolabs has expanded its integrated microfluidics portfolio to enhance high-throughput antibody discovery, addressing key challenges in throu...
Quantum BioPharma Targets Neurological Disorders with Dual Pipeline
Quantum BioPharma is developing Lucid-MS for multiple sclerosis and unbuzzd for alcohol intoxication, addressing significant unmet needs in neurologic...
Oncotelic Therapeutics Publishes Preclinical Data Supporting Intravenous Cancer Therapy Sapu003
Oncotelic Therapeutics and Sapu Nano published preclinical data in Biomedicines supporting Sapu003, an intravenous formulation of everolimus, demonstr...
Kairos Pharma Partners with Bayer to Test Combination Therapy for Advanced Prostate Cancer
Kairos Pharma Ltd. collaborates with Bayer to evaluate its antibody ENV-105 combined with XOFIGO for metastatic castration-resistant prostate cancer, ...
VERAXA Biotech Receives Positive Regulatory Feedback for BiTAC-TCE Program
VERAXA Biotech AG has received Scientific Advice from Germany's Paul-Ehrlich-Institute supporting the development strategy for its lead BiTAC-TCE prog...
VivoSim Labs Raises $4 Million in Private Placement with Healthcare Investor
VivoSim Labs announced a $4 million private placement with a healthcare-focused institutional investor to fund working capital and general corporate p...
Greenwich LifeSciences Advances Phase 3 Trial for Breast Cancer Immunotherapy GLSI-100 with Expanded Study Design
Greenwich LifeSciences announced progress in its Phase 3 FLAMINGO-01 trial for GLSI-100, including DSB approval to continue, plans to expand enrollmen...
Quantum BioPharma Targets Brain Disorders with Two-pronged Pipeline
Quantum BioPharma Ltd. is advancing treatments for multiple sclerosis and alcohol intoxication, addressing significant unmet needs in neurological car...
American Fusion Inc. Receives Texas Registration for Texatron Fusion Engine Testing
American Fusion Inc. (OTC: AMFN) obtained a Texas Certificate of Registration for Industrial Radiation Machines, allowing testing of its Texatron Fusi...
WHO-Commissioned Study Finds No Evidence Linking Mobile Phones to Brain Cancer
A comprehensive review commissioned by the World Health Organization found no evidence that mobile phone use causes brain cancer, potentially easing l...
Quantum BioPharma Reaches Halfway Milestone in MS Imaging Study, Early Data Shows Promise
Quantum BioPharma announced that its PET imaging study for multiple sclerosis has enrolled half its patients, with preliminary data showing a meaningf...
GeoVax's GEO-MVA Platform Aligns with HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy
GeoVax highlights that its GEO-MVA vaccine platform aligns with the U.S. Department of Health and Human Services Administration for Strategic Prepared...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform, Advancing Toward Clinical Development
VERAXA Biotech announced regulatory feedback from Germany's Paul-Ehrlich-Institute providing clarity on its BiTAC-TCE cancer therapy program, supporti...
VERAXA Biotech Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform
VERAXA Biotech AG (NASDAQ: VRXA) received Scientific Advice from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, providing clarity on dev...
Regentis Biomaterials Receives Japan Patent Allowance for GelrinC Manufacturing Technology
Regentis Biomaterials announced a Japan patent allowance for its organic solvent-free manufacturing process for GelrinC, a regenerative knee cartilage...
MindBio Therapeutics Advances Voice-Based AI Tech for Real-Time Impairment Detection
MindBio Therapeutics is developing a non-invasive AI voice analysis platform for real-time drug and alcohol impairment detection, targeting safety-cri...
Study Links Gut Microbial Metabolites to Enhanced Cancer Immunotherapy Sensitivity
A study shows that metabolites from gut bacteria can improve responses to cancer immunotherapy, highlighting the microbiome's role in treatment effica...
SS Innovations Appoints Veteran Medtech Finance Executive Sarah M. Romano as CFO Amid Global Expansion
SS Innovations International appointed Sarah M. Romano as CFO to bolster financial leadership as it pursues FDA clearance for its SSi Mantra surgical ...
Creative Biolabs Integrates Microfluidics and Electrochemical Biosensors to Accelerate Next-Generation POCT Diagnostics
Creative Biolabs has expanded its development platform by integrating microfluidics and electrochemical biosensors to address challenges in point-of-c...